Evidence map›Paper›PMID 37091913›Full record

ArticleInternational journal of cardiology. Heart & vasculature2023

Echocardiography in inflammatory heart disease: A comparison of giant cell myocarditis, cardiac sarcoidosis, and acute non-fulminant myocarditis.

Emanuele Bobbio, Johanna Amundsen, Anders Oldfors, Entela Bollano, Niklas Bergh, Marie Björkenstam, Marco Astengo, Kristjan Karason, Sinsia A Gao, Christian L Polte

Open access · goldAbstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Recent highlights on myocarditis and cardiomyopathies from theInternational journal of cardiology. Heart & vasculature · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Emanuele BobbioDepartment of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Johanna AmundsenDepartment of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Anders OldforsDepartment of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Entela BollanoDepartment of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Niklas BerghDepartment of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Marie BjörkenstamDepartment of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Marco AstengoDepartment of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Kristjan KarasonDepartment of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Sinsia A GaoDepartment of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Christian L PolteDepartment of Clinical Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden.
Sahlgrenska University Hospital · SEUniversity of Gothenburg · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Giant cell myocarditis (GCM) and cardiac sarcoidosis (CS) are, in contrast to acute non-fulminant myocarditis (ANFM), rare inflammatory diseases of the myocardium with poor prognosis. Although echocardiography is the first-line diagnostic tool in these patients, their echocardiographic appearance has so far not been systematically studied. Methods: We assessed a total of 71 patients with endomyocardial biopsy-proven GCM (n = 21), and CS (n = 25), as well as magnetic resonance-verified ANFM (n = 25). All echocardiographic examinations, performed upon clinical presentation, were reanalysed according to current guidelines including a detailed assessment of right ventricular (RV) dysfunction. Results: In comparison with ANFM, patients with either GCM or CS were older (mean age (±SD) 55 ± 12 or 53 ± 8 Conclusions: Both GCM and CS have an echocardiographic and clinical appearance that is distinct from ANFM. However, the method cannot further differentiate between the two rare entities. Consequently, echocardiography can strengthen the initial clinical suspicion of a more severe form of myocarditis, thus warranting a more rigorous clinical work-up.

Indexed as

Cardiac sarcoidosisEchocardiographyGiant cell myocarditisInflammatory heart diseaseMyocarditisRight ventricular dysfunction

Identifiers

PMID37091913
PMCPMC10120371
OpenAlexW4362706381

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.